Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.10 USD
Change Today -0.52 / -3.82%
Volume 70.3K
TCON On Other Exchanges
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

tracon pharmaceuticals inc (TCON) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/15 - $21.00
52 Week Low
02/11/15 - $9.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tracon pharmaceuticals inc (TCON) Related Businessweek News

No Related Businessweek News Found

tracon pharmaceuticals inc (TCON) Details

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is also planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, it has completed various Phase I and Phase II clinical trials of TRC105 for the indications, such as solid tumors, glioblastoma, hepatocellular carcinoma, and renal cell carcinoma, as well as breast, prostate, bladder, and ovarian cancers. Further, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals, Inc. has collaboration agreements with National Cancer Institute and Santen. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

15 Employees
Last Reported Date: 03/11/15
Founded in 2004

tracon pharmaceuticals inc (TCON) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $395.0K
Chief Financial Officer
Total Annual Compensation: $69.2K
Chief Business Officer
Total Annual Compensation: $251.5K
Compensation as of Fiscal Year 2014.

tracon pharmaceuticals inc (TCON) Key Developments

TRACON Pharmaceuticals Announces Positive Results of TRC105 Clinical Trials in Sarcoma and Liver Cancer at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting

TRACON Pharmaceuticals reported positive results from two separate clinical trials combining TRC105 with approved VEGF inhibitors. Data were presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. The first study was the dose escalation Phase 1b portion of a Phase 1b/2 study of TRC105 in combination with Votrient® (pazopanib) in 18 patients with advanced soft tissue sarcomas. All patients in the Phase 1b study received at least one prior chemotherapy regimen, and prior treatment with Votrient was allowed. The median number of prior therapies for patients in the Phase 1b study was two, and ranged from one to seven. All patients were treated with the combination of TRC105 given once weekly (8 or 10 mg/kg) and Votrient at its approved dose of 800 mg per day. The combination was well-tolerated without the development of dose limiting toxicity. Six of 18 patients (33%) had tumor reductions of greater than 10% by RECIST, and median progression-free survival for patients to date is 5.9 months. One patient with angiosarcoma, a tumor type known to express high levels of endoglin, has an ongoing complete response by RECIST and remains on treatment at week 30. In addition, in the ongoing Phase 2 portion of the study, a patient with angiosarcoma also demonstrated a complete response to treatment that is ongoing at this time. The Phase 1b portion of the study has completed enrollment, and the Phase 2 portion of the study combining TRC105 with Votrient continues to enroll patients.

TRACON Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 03:30 PM

TRACON Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 03:30 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Charles P. Theuer, Chief Executive Officer, President and Director.

TRACON Pharmaceuticals, Inc.'s TRC105 Receives FDA Fast Track Designation

TRACON Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of TRC105 in patients with advanced renal cell carcinoma (RCC) that have progressed following treatment with one inhibitor of the VEGF pathway in combination with standard dose Inlyta® (axitinib). The FDA created the Fast Track designation process to facilitate the development and expedite the review of drugs to treat serious diseases and address unmet medical needs. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application, if relevant criteria are met. TRACON is sponsoring a multicenter, open-label, randomized clinical trial of TRC105 in combination with AXitinib in patients with Advanced or metastatic RCC (TRAXAR). The primary endpoint of the Phase 2b study is progression-free survival. Approximately 150 patients with clear cell RCC who have failed one prior VEGF inhibitor are expected to enroll in the study. Patients may have also failed one prior mTOR inhibitor and one prior immunotherapy.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TCON:US $13.10 USD -0.52

TCON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TCON.
View Industry Companies

Industry Analysis


Industry Average

Valuation TCON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.0x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRACON PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at